Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.

JCO precision oncology - 1 Apr 2022

Capone Stephen, Ketonen Leena, Weathers Shiao-Pei, Subbiah Vivek

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Morpholines
Share to Mutation
Share to Pyrimidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrroles

Share to Receptor, Fibroblast Growth Factor, Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 35507888
DOI: 10.1200/PO.21.00371
PMCID: PMC9200395

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.PMID 35507888Read ↗

Dabrafenib for Pilocytic Astrocytoma With BRAF V599ins.Semantic proximity Read ↗

Impact of BRAF/MEK inhibitor on BRAF V600E-mutated pilocytic astrocytoma.Semantic proximity Read ↗

MEK Inhibition in a Pilocytic Astrocytoma With a Rare KRAS Q61R Mutation in a Young Adult Patient: A Case Report.Semantic proximity Read ↗

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.Semantic proximity Read ↗

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Semantic proximity Read ↗

The morphologic and molecular characteristics of pilocytic astrocytomas and the role of MAPK pathway: what does not kill you makes you stronger.Semantic proximity Read ↗

The role of BRAF-targeted therapy in astrocytomas: a review.Semantic proximity Read ↗

Dabrafenib and trametinib in BRAFV600E mutated glioma.Semantic proximity Read ↗

The involvement of the MAPK pathway in pilocytic astrocytomas.Semantic proximity Read ↗

Punctate palmoplantar keratoderma type 1: a novel AAGAB mutation and efficacy of etretinate.Semantic proximity Read ↗

Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.Semantic proximity Read ↗

Poziotinib for uncommon ERBB mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.